MedPath

Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.

Phase 4
Completed
Conditions
Knee Osteoarthritis
Interventions
Procedure: platelet rich plasm
Procedure: Isotonic Saline Solution
Registration Number
NCT03086759
Lead Sponsor
Federal University of São Paulo
Brief Summary

Osteoarthritis of the knee is a very prevalent disease. However, there are few therapeutic options for its patients. Platelet-rich plasma is a treatment option for chronic pain. If proven to be effective in its intra-articular use, Platelet-rich plasma may help in the treatment of these patients.

Goal:

Primary objective: To compare effectiveness in improving pain and function and the medium-term tolerance (12 weeks) of intra-articular injection of Platelet-rich plasma versus intraarticular injection of triamcinolone hexacetonide in patients with symptomatic primary knee osteoarthritis.

Secondary objective: To compare the medium-term effectiveness of intra-articular injection of Platelet-rich plasma versus intra-articular injection of triamcinolone hexacetonide to improve synovial hypertrophy and quality of life in these patients.

Methods: A prospective randomized controlled double-blind study with three groups (each with n = 33) of patients with symptomatic osteoarthritis of knees who will receive intra-articular infiltration in a single moment. Patients will be allocated to one of three groups: 1) Platelet-rich plasma group: patients who will receive plasma; 2) triamcinolone hexacetonide Group: patients who will receive 40mg of triamcinolone hexacetonide; And 3) Isotonic saline solution group: patients who will receive isotonic saline solution. The patients will be evaluated by "blind" evaluators in 4 assessment times up to 12 weeks of follow-up through clinical assessment instruments (rest and movement pain, joint edema, goniometry, clinical improvement scale, quality of life questionnaire as the SF36), functional (Womac questionnaire, M. Lequesne Functional Knee Index, 6 min walk test, Time up and go test), and ultrasound test (quantitative and semiquantitative measurement of synovial hypertrophy and semiquantitative Power Doppler).

Statistics: The following statistical tests will be used according to the need: Student's t test, Mann-whitney, Pearson's chi-square test and ANOVA for repeated measures. A statistical significance of 5% will be considered.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
99
Inclusion Criteria
  • primary knee osteoarthritis
  • degree II and II in Kellgren & Lawrence classification
  • pain duration: more than three months
  • pain in the visual analogue scale between 4 and 8cm
  • agree in participate and sign the consent form
Exclusion Criteria
  • secondary knee osteoarthritis
  • skin lesion in knee
  • intraarticular joint injection in the previous three months
  • steroids use in the previous 30 days
  • degree I or IV in Kellgren & Lawrence classification
  • inflammatory arthritis, gout and pseudo-gout
  • cancer
  • previous surgery in knee
  • cardiovascular and respiratory disease that change functional status
  • pregnancy and breastfeed
  • coagulation disturb
  • bacterial infection
  • handicapped
  • NSAIDs and Platelet anticoagulant in the previous month

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Triamcinolone Hexacetonide groupTriamcinolone Hexacetonide-
Platelet rich plasm groupplatelet rich plasm-
Isotonic Saline Solution groupIsotonic Saline Solution-
Primary Outcome Measures
NameTimeMethod
Change in painBaseline, after 4, 8, 12 and 48 weeks

Evaluated using a visual analogue scale

Secondary Outcome Measures
NameTimeMethod
Change in functional capacityBaseline, after 4, 8, 12 and 48 weeks

Using the time to up and go test

Change in joint edemaBaseline, after 4, 8, 12 and 48 weeks

Evaluated using a visual analogue scale

Change in range of motionBaseline, after 4, 8, 12 and 48 weeks

Evaluated using goniometry

Change in a clinical improvement scaleBaseline, after 4, 8, 12 and 48 weeks

Evaluated using an improvement scale

Change in quality of lifeBaseline, after 4, 8, 12 and 48 weeks

Using the SF-36 questionnaire

Changing in quantitative and semiquantitative measurement of synovial hypertrophy and semiquantitative Power DopplerBaseline, after 4, 8, 12 and 48 weeks

Using an ultrasound exam

Trial Locations

Locations (1)

Universidade Federal de Sao Paulo

🇧🇷

Sao Paulo, SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath